One of the most profound natural substances in a long time...the enormous NAFLD (non-alcoholic fatty liver disease) health crisis has an answer, and it’s not a drug...
The graphic above shows data from a 16 week double blind, placebo controlled randomized clinical trial. Participants were type 2 diabetics. They received either 600 mg of Bergacyn once daily or placebo. The results were quite remarkable, showing reversal of liver fibrosis, decrease in liver enzymes, improvement in cardiovascular inflammation and endothelial function.
Bergacyn Clinically Shown to Reduce Liver Fat in Clinical Trial
Bergamot-cynara extract helps reduce liver fat and inflammation in diabetes, according to a new study in which 80 subjects participated.
Results of a recent clinical study show that Bergacyn, a patented botanical extract blend for digestive and metabolic support marketed in the U.S. by DolCas Biotech, has beneficial effects in reducing liver steatosis (excess fat in the liver), inflammation, and oxidative stress in type 2 diabetes.
The nutraceutical, which was introduced to the U.S. market by DolCas last fall, has a 17% flavonone polyphenol and 5% cynaropicrin content when blended in process with micronized bergamot pulp fibers.
The double-blind, placebo-controlled study conducted by Musolino, Gliozzi, Bombardelli, et alia spanned 16 weeks, and its results were published this month in The Journal of Traditional and Complementary Medicine.
“Bergacyn’s unique blending of a high polyphenol extract of bergamot and a high-sesquiterpene extract of artichoke leaf showed a novel synergistic benefit that was more than additive, when compared to stand-alone, single doses of bergamot or cynara extract,” Shavon Jackson-Michel, DolCas medical and scientific affairs director, said. “The potentizing action as a function of the patented process used enhances Bergacyn’s bioactivity.”
80 subjects were divided into four treatment subgroups: placebo, 600 milligrams of Bergacyn, 600 milligrams of a non-proprietary bergamot extract blend, and a 600 milligram cynara extract blend.
Statistically significant changes, with a P-value of less than 0.05, were seen in all parameters related to non-alcoholic fatty liver disease pateints in the Bergacyn group.
Biopsies showed that liver fat accumulation regressed two levels on average in the Bergacyn group, from severe to mild, according to the hepatorenal index parameter.
Unlike other inverventions, Bergacyn saw more substantial reductions in AST (aspartate aminotransferase) and ALT (alanine aminotransferase), liver damage enzymes that define the more destructive stages of NAFLD. ALT and AST levels were reduced by 15 and 18 points respectively with a P-value of less than 0.05 in the Bergacyn group. The groups using standalone bergamot or cynara extracts saw ten-point reductions on average, and there were no AST or ALT changes in the control group.
The Bergacyn group also recorded the greatest quantitative increase in antioxidation and fibrosis intervention (via reduced scar tissue mediators) and anti-inflammatory action (via reduced TNF-?), all with a P-value of less than 0.001.
The significantly improved biomarkers were the suggested mechanism in additionally improving endothelial function for the Bergacyn group (p<0.05). The array of benefits in this study led researchers to conclude that evidence supports Bergacyn’s multi-angled approach in supporting NAFLD-complicated diabetes subjects.
NAFLD has doubled every two decades since 1988, and now affects about 25% of the human population. Paralleling the obesity epidemic, NAFLD is now projected to cost Americans more than $1 trillion over the next ten years and result in rising cases of advanced cardiovascular disease and liver failure, according to Bergacyn.
Bergacyn claims it is the first solvent- and excipient-free extract to exhibit proven liver support in steatosis. The condition, which is largely attributable to lifestyle choices, is metabolically active, setting the stage for chronic health concerns to develop or for existing ones to worsen.
This is a content preview space you can use to get your audience interested in what you have to say so they can’t wait to learn and read more. Pull out the most interesting detail that appears on the page and write it here.
Musolino, V et al, Journal of Traditional and Complementary Medicine.
Background and Aim: Non-Alcoholic Fatty Liver Disease (NAFLD) represents a risk factor for cardiovascular diseases. NAFLD is worsened by the simultaneous occurrence of type 2 diabetes mellitus (T2DM) causing an enhancement of inflammatory and fibrotic processes. Although insulin resistance appears the link between NAFLD and T2DM, current pharmacological treatments of T2DM failed to produce relevant benefits in preventing T2DM-related liver dysfunction. In this randomized, double blind, placebo-controlled clinical study, we evaluated the effect of Bergacyn, an innovative formulation originating from the combination of Bergamot Polyphenolic Fraction (BPF) and Cynara cardunculus (CyC). Experimental procedure: 80 adult patients with a history of at least 12 months of T2DM and NAFLD received orally BPF (300 mg/daily) Cyc (300 mg/daily), separately or formulated in combination 50/50% (Bergacyn; 300 mg/daily), or placebo all containing 300 mg of bergamot albedo fibers micronized and co-grinded as excipients. Results and Conclusion: Serum measurements and liver ultrasound analyses showed that concomitant administration of BPF and CyC produced significant improvement of NAFLD biomarkers in patients with T2DM. This effect was associated with a substantial reduction of oxidative stress/inflammatory biomarkers, thus contributing to a significant improvement of NO-mediated reactive vasodilation. Furthermore, the effect of Bergacyn showed a synergistic effect of both extracts, thus suggesting that this peculiar formulation represents a novel therapeutic strategy to counteract vascular inflammation and endothelial dysfunction in patients suffering from T2DM and NAFLD. Further studies in larger cohort of diabetic patients are required to better identify the potential of Bergacyn on metabolic disorders accompanying T2DM and NAFLD.
Bergacyn® supports healthy liver fat levels in clinical studies *
Bergacyn® is the first, solvent-FREE, branded botanical ingredient of its kind to establish a proven liver support mechanism in populations that have accumulated excess liver fat. Overly excessive fat in the liver, generally brought on by poor lifestyle choices, is metabolically active and is believed to set the stage for chronic diseases. Bergacyn’s affinity to the liver and support of healthy immune and inflammatory function provides antioxidant, lipid and glucose metabolism support, helping to unburden an often overlooked organ.
With over 2.5 billion people estimated to be suffering from metabolic syndrome and obesity, significant drivers in the development of hepatic steatosis (fatty liver) and its sequela, Bergacyn® intake proved to be especially appropriate for reducing liver fat in overweight subjects, those 50-years and older, and those with central body fat accumulation. Independent of caloric restriction, Bergacyn® intake over 12 weeks resulted in significantly more weight loss, as compared to placebo (p=0.004), extending additional, complementary benefit in populations seeking overall better health.
Bergacyn is changing the way we think of supporting the liver with botanicals. Whereas ‘liver support’ to the consumer of the past may have simply meant ‘detox’, seasonal or otherwise; the ‘liver support’ story of the future will absolutely tie into the narrative of lifestyle, cardiovascular health and metabolic efficiency.
Bergacyn® is a patented extract of Bergamot fruit and Artichoke leaf.
Bergacyn® is a science-backed, process-patented, low-dose, powerhouse blend of botanical extracts from the Italian Bergamot citrus fruit and wild-variety of Italian Cynara cardunculus leaf.
Bergacyn® is not simply a blend of 2 powdered herbs. The synergism activated by the patented, in-process extraction method significantly reduces the clinically substantiated requirement for the individual ingredients. Moreover, the Cynara used in Bergacyn is not the standard industry variety of cardunculus, but a wild ancestor thereof, shown to be significantly richer in the anti-inflammatory sesquiterpene, cyanopicrin. Cyanopicrin has proven TNF-α inhibitory and anti-proliferative activity. Cyanopicrin effectively complements the already well-characterized Bergamot flavonoid fraction, to be more effective than Bergamot alone in targeting metabolically-active liver fat.
The proprietary addtion of pulp fibers from the bergamot fruit round off this high-performing extract, providing additional polyphenols and lipid-absorbing benefits that potentiate the other bergamot and cynara actives.
Bergacyn’s profile is unique to it’s growing region and patented process.
Bergacyn’s unique growing terrain, Reggio Calabria, is the region nestled along the ‘toe of Italy’s boot’ spanning both coasts of the Mediterranean Sea and divided in the middle by the southern-most chain of the Appinnine Mountains. This uniquely tropical, Saharan-desert dusted, coastal and mountainous region produces a favorable and exclusive profile of flavonoids and sesquiterpenes in the Bergamot fruit and Artichoke (Cynara) leaf that are unlike any of the related species of these botanicals found anywhere else in the world. These actives are extracted, using a 100% solvent-FREE, patented process that is both synergizing and bioavailability-enhancing.